Initial Data From Aastrom Biosciences, Inc. (ASTM)'s IMPACT-DCM Trial Presented At International Society for Cellular Therapy Annual Meeting by Amit N. Patel, M.D.
5/5/2009 12:36:00 PM
ANN ARBOR, Mich., May 5, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced today that Dr. Amit N. Patel, Associate Professor of Surgery at the University of Utah School of Medicine and the National Principal Investigator of the Company's U.S. Phase II IMPACT-DCM clinical trial, presented initial trial data during an oral presentation today at the International Society for Cellular Therapy (ISCT) annual meeting in San Diego, California. The clinical trial is evaluating Aastrom's Cardiac Repair Cells (CRCs) for the treatment of patients suffering from both ischemic and non-ischemic dilated cardiomyopathy (DCM), a severe form of chronic heart failure. Currently, 13 of 40 patients have been enrolled in the trial, and enrollment is on target to be completed by the end of calendar year 2009.